mAbs (Jan 2021)
A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351
- Chunyin Gu,
- Xiaodan Cao,
- Zongda Wang,
- Xue Hu,
- Yanfeng Yao,
- Yiwu Zhou,
- Peipei Liu,
- Xiaowu Liu,
- Ge Gao,
- Xiao Hu,
- Yecheng Zhang,
- Zhen Chen,
- Li Gao,
- Yun Peng,
- Fangfang Jia,
- Chao Shan,
- Li Yu,
- Kunpeng Liu,
- Nan Li,
- Weiwei Guo,
- Guoping Jiang,
- Juan Min,
- Jianjian Zhang,
- Lu Yang,
- Meng Shi,
- Tianquan Hou,
- Yanan Li,
- Weichen Liang,
- Guoqiao Lu,
- Congyi Yang,
- Yuting Wang,
- Kaiwen Xia,
- Zheng Xiao,
- Jianhua Xue,
- Xueyi Huang,
- Xin Chen,
- Haixia Ma,
- Donglin Song,
- Zhongzong Pan,
- Xueping Wang,
- Haibing Guo,
- Hong Liang,
- Zhiming Yuan,
- Wuxiang Guan,
- Su-Jun Deng
Affiliations
- Chunyin Gu
- Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai, People’s Republic of China
- Xiaodan Cao
- Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai, People’s Republic of China
- Zongda Wang
- Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai, People’s Republic of China
- Xue Hu
- State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People’s Republic of China
- Yanfeng Yao
- Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, People’s Republic of China
- Yiwu Zhou
- Department of Forensic Medicine, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China
- Peipei Liu
- Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai, People’s Republic of China
- Xiaowu Liu
- Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai, People’s Republic of China
- Ge Gao
- Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, People’s Republic of China
- Xiao Hu
- State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People’s Republic of China
- Yecheng Zhang
- State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People’s Republic of China
- Zhen Chen
- State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People’s Republic of China
- Li Gao
- Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai, People’s Republic of China
- Yun Peng
- Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, People’s Republic of China
- Fangfang Jia
- Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai, People’s Republic of China
- Chao Shan
- State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People’s Republic of China
- Li Yu
- Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai, People’s Republic of China
- Kunpeng Liu
- State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People’s Republic of China
- Nan Li
- Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai, People’s Republic of China
- Weiwei Guo
- State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People’s Republic of China
- Guoping Jiang
- Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai, People’s Republic of China
- Juan Min
- Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, People’s Republic of China
- Jianjian Zhang
- Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai, People’s Republic of China
- Lu Yang
- Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai, People’s Republic of China
- Meng Shi
- Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai, People’s Republic of China
- Tianquan Hou
- Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai, People’s Republic of China
- Yanan Li
- Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai, People’s Republic of China
- Weichen Liang
- Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai, People’s Republic of China
- Guoqiao Lu
- Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai, People’s Republic of China
- Congyi Yang
- Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai, People’s Republic of China
- Yuting Wang
- Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai, People’s Republic of China
- Kaiwen Xia
- Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai, People’s Republic of China
- Zheng Xiao
- Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai, People’s Republic of China
- Jianhua Xue
- Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai, People’s Republic of China
- Xueyi Huang
- Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai, People’s Republic of China
- Xin Chen
- Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai, People’s Republic of China
- Haixia Ma
- Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, People’s Republic of China
- Donglin Song
- Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, People’s Republic of China
- Zhongzong Pan
- Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai, People’s Republic of China
- Xueping Wang
- Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai, People’s Republic of China
- Haibing Guo
- Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai, People’s Republic of China
- Hong Liang
- Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai, People’s Republic of China
- Zhiming Yuan
- Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, People’s Republic of China
- Wuxiang Guan
- Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, People’s Republic of China
- Su-Jun Deng
- Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai, People’s Republic of China
- DOI
- https://doi.org/10.1080/19420862.2021.1930636
- Journal volume & issue
-
Vol. 13,
no. 1
Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes coronavirus disease-2019 (COVID-19), interacts with the host cell receptor angiotensin-converting enzyme 2 (hACE2) via its spike 1 protein during infection. After the virus sequence was published, we identified two potent antibodies against the SARS-CoV-2 receptor binding domain (RBD) from antibody libraries using a phage-to-yeast (PtY) display platform in only 10 days. Our lead antibody JMB2002, now in a Phase 1 clinical trial (ChiCTR2100042150), showed broad-spectrum in vitro blocking activity against hACE2 binding to the RBD of multiple SARS-CoV-2 variants, including B.1.351 that was reportedly much more resistant to neutralization by convalescent plasma, vaccine sera and some clinical-stage neutralizing antibodies. Furthermore, JMB2002 has demonstrated complete prophylactic and potent therapeutic efficacy in a rhesus macaque disease model. Prophylactic and therapeutic countermeasure intervention of SARS-CoV-2 using JMB2002 would likely slow down the transmission of currently emerged SARS-CoV-2 variants and result in more efficient control of the COVID-19 pandemic.
Keywords
